The short answer
Treatment categories may include intensive or lower-intensity systemic therapy, targeted medicines for selected findings, supportive care, transplant, and clinical trials. The right comparison starts with disease status and the person's goals.
Options may include intensive or lower-intensity systemic therapy, targeted medicines for selected findings, supportive care, transplant, and clinical trials.
Planning may depend on subtype, gene and chromosome findings, fitness, organ function, treatment urgency, and goals.
Compare goals, evidence, time burden, important harms, monitoring, and alternatives.
Ask about transplant, cellular therapy, and trials early enough for a meaningful choice.
Choose how you want to understand this
The full explanation.
Start with fitness for intensive chemotherapy
The first big decision in AML treatment is fitness. Can you tolerate intensive chemotherapy? This depends on age, other health conditions, and overall fitness, not age alone. Ask your team directly how they are weighing your fitness for intensive treatment.
Induction: the first, intensive phase
For those fit enough, treatment starts with induction chemotherapy. It is often called "7+3." This combines seven days of a drug called cytarabine. It adds three days of an anthracycline drug, such as daunorubicin or idarubicin. The goal is to clear leukemia cells from the blood and marrow. Then normal blood cell production can restart. This phase usually means a hospital stay of several weeks. Blood counts drop sharply before they recover.
Consolidation: staying in remission
Once induction achieves remission, consolidation chemotherapy follows. Built again around cytarabine, it aims to kill any leukemia cells left behind. For higher-risk AML, a stem cell transplant may follow. It uses cells from a donor, to lower the chance the leukemia returns.
Targeted therapy based on your mutation
AML treatment increasingly depends on your genes. Doctors look for specific gene changes in your leukemia cells. Midostaurin, quizartinib, and gilteritinib target FLT3 mutations. Ivosidenib and enasidenib target IDH1 and IDH2 mutations. Gemtuzumab ozogamicin targets a marker called CD33. Ask which mutations your leukemia was tested for. A positive result can add a targeted drug to your regimen, or change which one is used.
Gentler options for less fit patients
Some people cannot tolerate intensive chemotherapy. For them, venetoclax combined with a lower-intensity drug is a common option. It controls the leukemia with less physical strain than full induction chemotherapy. It is not usually curative on its own.
Weighing benefits and harms
Intensive induction chemotherapy offers the best chance at a cure. That is true for people who can tolerate it. But blood counts drop low during treatment. That brings a real risk of serious infection, so it needs close hospital monitoring.
Targeted drugs like FLT3 and IDH inhibitors are pills, often easier day to day. But they carry their own risk: a reaction called differentiation syndrome, which needs prompt recognition.
Stem cell transplant offers durable control for higher-risk disease. It carries risks too. One is infection. Another is graft-versus-host disease, where donor immune cells attack the body.
What to ask your team
- Am I a candidate for intensive induction chemotherapy?
- Which gene mutations were found, and does that change my treatment?
- What does the hospital stay for induction look like?
- Is a stem cell transplant part of my plan, and from what kind of donor?
- What symptoms during low blood counts need an immediate call?
When to get help sooner
- Call 911 or go to an emergency department if you are struggling to breathe, or you have bleeding you cannot stop.
- Call your care team immediately, at any hour, if you have a temperature of 100.4°F (38°C) or higher, chills, a cough, a stiff neck, or pain when you pass urine. Counts stay very low for weeks after induction, and CDC says an infection during cancer treatment can be life threatening and needs urgent medical attention. Call before taking anything for the fever, and if nobody answers quickly, go to an emergency department.
- Call your care team the same day if you take an IDH or FLT3 inhibitor and develop fever, breathlessness, bone pain, sudden weight gain, or swelling of the arms or legs. That combination is how differentiation syndrome starts. The enasidenib label carries a boxed warning that it can be fatal if it is not treated, and treatment is corticosteroids. Go to an emergency department if breathing is hard.
- Call your care team within a day or two if you notice new bruising, nosebleeds, or a rash of small red or purple dots on the skin.
Sources
- National Cancer Institute — Acute Myeloid Leukemia Treatment (PDQ).
- National Cancer Institute — Infection and Neutropenia During Cancer Treatment.
- DailyMed — IDHIFA (enasidenib) prescribing information, boxed warning on differentiation syndrome.
- National Cancer Institute — Gilteritinib Fumarate, for its use in relapsed or refractory FLT3-mutated AML.
Words to know
Tap any term to see what it means.
Common questions
What decides my treatment first, my age or something else?
Fitness for intensive chemotherapy is the first big decision, and it depends on age, other health conditions, and overall fitness rather than age alone. Ask your team directly how they are weighing that in your case.
What does 7+3 mean?
It is the usual induction regimen for people fit enough for intensive treatment: seven days of cytarabine plus three days of an anthracycline such as daunorubicin or idarubicin. The goal is to clear leukemia cells so normal blood cell production can restart. It usually means a hospital stay of several weeks, with counts dropping sharply before they recover.
Why does my team keep talking about mutations?
AML treatment increasingly depends on the gene changes in your leukemia cells. Midostaurin, quizartinib, and gilteritinib target FLT3 mutations. Ivosidenib and enasidenib target IDH1 and IDH2. Gemtuzumab ozogamicin targets a marker called CD33. A positive result can add a targeted drug to your regimen or change which one is used.
What if I am not fit for intensive chemotherapy?
Venetoclax combined with a lower-intensity drug is a common option. It controls the leukemia with less physical strain than full induction chemotherapy. It is not usually curative on its own.
What is consolidation for?
Once induction achieves remission, consolidation chemotherapy, built again around cytarabine, aims to kill any leukemia cells left behind. For higher-risk AML a stem cell transplant using donor cells may follow, to lower the chance the leukemia returns.
Questions to ask your doctor
Being prepared helps you get the most out of your appointments. Save or print these questions.
Tap a question to save it to your list (kept on this device).
Your next step
Turn this guide into a short list for your care team.
Speak With Trained Specialists & Human Navigators
Cancer Explained provides educational guidance, but does not replace trained specialists, social workers, or your medical team.
Talk to a trained cancer information specialist
Free, confidential assistance from NCI Cancer Information Service via phone, chat, or email.
Contact your oncology team
Locate after-hours contact numbers, portal messages, or urgent triage phone lines.
Find a patient navigator
Get one-on-one help with appointments, logistics, translation, and care coordination.
Find a genetic counselor
Discuss inherited mutation risk, family history, and genetic testing options.
Find an oncology social worker
Access emotional counseling, family support groups, and mental health resources.
Find a financial navigator
Locate copay assistance foundations, grant programs, and lodging/travel support.
Find a clinical-trial specialist
Search matching studies and speak with NCI trial information specialists.
Get urgent help
Immediate emergency guidance for fever (>100.4°F during chemo), severe pain, or shortness of breath.
Help Us Improve This Guide
Did this explanation answer your question and help you determine your next step?
Know someone who needs this?
Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.
Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.
Plain-language explanation of the published sources cited on this page. AI-assisted, source-checked, not clinician-reviewed.
Sources last checked: 2026-08-13 what this meansLast updated: 2026-08-20Next planned review: 2027-01-22
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status — Source checked. This page was written with AI assistance and checked line by line against the sources listed on it. That confirms the sources support what the page says. It is not a medical review, and it does not confirm the page is complete or right for your situation.
High-risk topic — talk to your care team. This topic can involve urgent, individual medical decisions. This page is general education only: it cannot tell you whether your situation is an emergency or what you personally should do. Follow your oncology team's instructions and contact them for individual guidance.
Human medical review: not completed. Pages here are not signed off by a clinician before they publish. That is not an oversight we are quietly working around: we restate published guidance and cite it, so the authority belongs to the source rather than to us, and every page names where its claims come from — you can verify us instead of trusting us. Where a volunteer clinician has reviewed a page, their name and credentials appear on it; where no name appears, no clinician has checked it. We are glad to have reviewers and are recruiting them, and we do not hold pages back waiting for one. Use this site to understand your situation and to ask better questions of the people treating you.
How this page was created
Cancer Explained does not originate medical claims. Every page restates guidance already published by the National Cancer Institute, the CDC, the USPSTF and the FDA, in plain language, with the source cited so you can check the original yourself. AI does the translating and organizing; automated checks test claims, citations, clarity and safety before anything publishes. We do not employ clinicians and do not intend to — our work is translation and navigation, not clinical judgment. Nothing here is personal medical advice, and no page can account for your particular situation.
Editorial status: Source checked — This page was written with AI assistance and checked line by line against the sources listed on it. That confirms the sources support what the page says. It is not a medical review, and it does not confirm the page is complete or right for your situation.
Human medical review: not completed. Pages here are not signed off by a clinician before they publish. That is not an oversight we are quietly working around: we restate published guidance and cite it, so the authority belongs to the source rather than to us, and every page names where its claims come from — you can verify us instead of trusting us. Where a volunteer clinician has reviewed a page, their name and credentials appear on it; where no name appears, no clinician has checked it. We are glad to have reviewers and are recruiting them, and we do not hold pages back waiting for one. Use this site to understand your situation and to ask better questions of the people treating you.
Read more about our editorial process, our use of AI, and our corrections policy.
Spotted a problem? Report an error — a factual mistake, broken or outdated source, confusing wording, or anything that seems unsafe. Please do not include names, medical record numbers, dates of birth, addresses, or other identifying medical information in your report.
After using this page, do you understand what to do next?
Anonymous — we only record the answer, never who gave it.
Related articles
Still have questions?
Educational answers, plain language
Free to print and share